XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.4
Revenue Components
 9 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Components Revenue Components
The following table provides information about the Company’s revenues for the three and nine months ended December 31, 2021 and 2020 (in thousands):
Three Months Ended December 31,Nine Months Ended December 31,
2021202020212020
Revenues:
Product revenue, net:
ORGOVYX$24,393 $— $53,535 $— 
MYFEMBREE2,429 — 4,133 — 
Richter product supply and royalties2,446 — 4,217 — 
Total product revenue, net29,268 — 61,885 — 
Pfizer collaboration revenue:
Amortization of upfront payment20,974 1,379 62,922 1,379 
Amortization of regulatory milestone4,198 — 16,931 — 
Total Pfizer collaboration revenue25,172 1,379 79,853 1,379 
Richter license and milestone revenue— — 31,667 33,333 
Total revenues$54,440 $1,379 $173,405 $34,712 
The Company began generating product revenue from sales of ORGOVYX and MYFEMBREE in the U.S. in January 2021 and June 2021, respectively. The Company records product revenue net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions. For the three and nine months ended December 31, 2021, product revenue, net also includes revenues related to product supply to Richter to support their European launches of $2.3 million and $4.1 million, respectively, as well as royalties on net sales of RYEQO in Richter’s Territory of $0.1 million and $0.2 million, respectively. There were no such revenues recorded in the comparable prior year periods.
Pfizer collaboration revenue for the three and nine months ended December 31, 2021 consists of the partial recognition of the upfront payment the Company received from Pfizer upon entering into the Pfizer Collaboration and License Agreement in December 2020 and of the regulatory milestone payment from Pfizer that was triggered upon the FDA approval of MYFEMBREE for the management of heavy menstrual bleeding associated with uterine fibroids on May 26, 2021. Pfizer collaboration revenue for the three and nine months ended December 31, 2020 consists of the partial recognition of the upfront payment the Company received from Pfizer in December 2020.
Richter license and milestone revenue for the nine months ended December 31, 2021 was $31.7 million, consisting of the recognition of a $15.0 million regulatory milestone payment from Richter that was triggered upon the European Commission approval of RYEQO for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age and $16.7 million of previously deferred revenue that was recognized upon the completion of the Company’s delivery of the remaining substantive relugolix combination tablet data packages to Richter. Richter license and milestone revenue for the nine months ended December 31, 2020 consists of the recognition of $33.3 million of the upfront and regulatory milestone payments the Company received from Richter in March and April 2020, respectively. There was no Richter license and milestone revenue for the three months ended December 31, 2021 and 2020.
See Note 8 for additional information regarding the Pfizer Collaboration and License Agreement and the Richter Development and Commercialization Agreement.